Toripalimab (JS001 ) Lenvatinib

Phase 1Small molecule

Toripalimab (JS001 ) Lenvatinib is one of 64 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 1

Active, not recruiting

Hepatocellular CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Viread

Gilead

Preclinical

1 2

Hepsera

Coreg

2 4

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

PD-1 Inhibitors

5 9

QL1706

Qilu Pharmaceutical Co., Ltd.

Preclinical

5 10

Alcohol

Astellas

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

N/ANot yet recruiting

Minimal Residual Disease

NCT06709274

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT03856411·465 enrolled

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT03581786·289 enrolled

Hepatocellular Carcinoma1 trial

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Terminated·SShanghai Junshi Bioscience Co., Ltd.·Phase 1/2·NCT03867370·40 enrolled

Minimal Residual Disease1 trial

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Not yet recruiting·GGuangdong Association of Clinical Trials·N/A·NCT06709274·342 enrolled

Nasopharyngeal Carcinoma1 trial

A Randomised, Open-label, Phase I Dose Exploration Study to Compare Single, Multiple, and Long-term Dosing of Toripalimab Injection (Subcutaneous) With Toripalimab Injection (IV) in Patients With Advanced Nasopharyngeal Carcinoma

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT05751486·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Toripalimab (JS001 ) Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab (JS001 ) Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toripalimab (JS001 ) Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

Toripalimab (JS001 ) Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Efficacy and Safety2 trials

Hepatocellular Carcinoma1 trial

Minimal Residual Disease1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News